PHENTOLAMINE MESYLATE

Other

Brand names: Oraverse

Pregnancy: Category CSubmucosal

Mechanism of Action

12.1 Mechanism of Action The mechanism by which OraVerse accelerates reversal of soft-tissue anesthesia and the associated functional deficits is not fully understood. Phentolamine mesylate, the active ingredient in OraVerse, produces an alpha-adrenergic block of relatively short duration resulting in vasodilatation when applied to vascular smooth muscle. In an animal model, OraVerse increased local blood flow in submucosal tissue of the dog when given after an intraoral injection of lidocaine 2% with 1:100,000 epinephrine.

Indications

1. INDICATONS AND USAGE OraVerse an alpha adrenergic blocker

is indicated for adult and pediatric patients ages 3 years and older for the reversal of soft-tissue anesthesia

i.e.

anesthesia of the lip and tongue

and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor. OraVerse

an alpha adrenergic blocker

FDA Warnings

WARNINGS AND PRECAUTIONS Myocardial infarction, cerebrovascular spasm, and cerebrovascular occlusion have been reported to occur following the intravenous or intramuscular administration of phentolamine, usually in association with marked hypotensive episodes or shock-like states which occasionally follow parenteral administration

Known Side Effects

5 documented side effects by frequency

Diarrhea

1-10%

Headache

1-10%

Drug Not Working

1-10%

High Blood Pressure

1-10%

Dizziness

1-10%

Community Discussions

No community discussions found for PHENTOLAMINE MESYLATE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Submucosal